Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. It also develops preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. The company was founded in 2017 and is headquartered in Watertown, Massachusetts. Show more

321 Arsenal Street, Watertown, MA, 02472, United States

Biotechnology
Healthcare

Market Cap

2.291B

52 Wk Range

$30.82 - $99.50

Previous Close

$60.04

Open

$60.65

Volume

291,392

Day Range

$60.21 - $62.44

Enterprise Value

1.533B

Cash

791.2M

Avg Qtr Burn

-43.3M

Insider Ownership

7.97%

Institutional Own.

-

Qtr Updated

12/31/25


Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Bitopertin Details
erythropoietic porphyrias (EPP), X-linked protoporphyria

Phase 3

Data readout

DISC-0974 (Hepcidin Suppression) Details
Inflammatory Bowel Disease With Anemia

Phase 2

Data readout

DISC-0974 Details
Myelofibrosis, Anemia

Phase 2

Data readout

Phase 2

Data readout

Bitopertin Details
Anemia, Rare genetic disease

Phase 1/2

Update

Phase 1b

Data readout

DISC-0974 Details
Anemia of non-dialysis-dependent chronic kidney disease (NDD-CKD)

Phase 1b

Data readout

GEM103 Details
Age-related macular degeneration

Failed

Discontinued

GEM103 Details
Wet age-related macular degeneration , Age-related macular degeneration

Failed

Discontinued